About the Procedure

WATCHMAN - How it Works

In non-valvular AF, >90% of stroke-causing clots that come from the left atrium are formed in the LAA3.

The WATCHMAN Implant is a minimally invasive, one-time procedure designed to reduce the risk of strokes that originate in the left atrial appendage (LAA).

minimally invasive icon

MINIMALLY INVASIVE

permanent implant icon

PERMANENT IMPLANT

procedure time icon

TYPICAL PROCEDURE IS LESS THAN 1 HOUR

hospital stay icon

24 HOUR AVERAGE HOSPITAL STAY

WATCHMAN LAAC Procedure

One-time procedure designed to reduce the risk of strokes that originate in the left atrial appendage (LAA).

1

Using a standard percutaneous technique, a guidewire and vessel dilator are inserted into the femoral vein.

2

The implant procedure is performed with fluoroscopy and transesophageal echocardiography (TEE). The interatrial septum is crossed using a standard transseptal access system.   

3

The access sheath is advanced over the guidewire into the left atrium and then navigated into the distal portion of the LAA over a pigtail catheter.

4

WATCHMAN is then deployed and released in the LAA.

5

Heart tissue grows over the WATCHMAN Implant and the LAA is permanently sealed. Patients remain on warfarin for at least 45 days post-procedure. 

6

A fully endothelialized device

Post-Implant Drug Regimen

Following the procedure, patients typically take warfarin and aspirin for 45 days or until there is adequate seal. After discontinuing warfarin, patients take clopidogrel and an increased dose of aspirin, followed by ongoing aspirin therapy. 

post-implant drug regimen

WATCHMAN is Implanted at Top Medical Institutions Across the Country

  • More than 550 major medical centers across the US are certified to implant WATCHMAN
  • The WATCHMAN physician training program involves multiple phases including didactic training, imaging training, training in patient selection, device selection, complication management, and optional physician proctoring
    • Individual physicians and/or the collective physician-team must be proficient in transseptal skills prior to entering the WATCHMAN Training Program 
WATCHMAN device

References:

  1. Blackshear JL., Odell JA. Annals of Thoracic Surg. 1996; 61: 755-759.

CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician. Rx only. Prior to use, please see the complete “Instructions for Use” for more information on Indications, Contraindications, Warnings, Precautions, Adverse Events, and Operator’s Instructions.​

INDICATIONS FOR USE​

The WATCHMAN Device is indicated to reduce the risk of thromboembolism from the left atrial appendage in patients with non-valvular atrial fibrillation who:​

  • Are at increased risk for stroke and systemic embolism based on CHADS2 or CHA2DS2-VASc scores and are recommended for anticoagulation therapy;​
  • Are deemed by their physicians to be suitable for anticoagulation therapy; and​
  • Have an appropriate rationale to seek a non-pharmacologic alternative to anticoagulation therapy, taking into account the safety and effectiveness of the device compared to anticoagulation therapy.

CONTRAINDICATIONS

Do not use the WATCHMAN® Device if:​

  • Intracardiac thrombus is present.​
  • An atrial septal defect repair or closure device or a patent foramen ovale repair or closure device is​ present.​
  • The LAA anatomy will not accommodate a device. See Table 45 (in the IFU).​
  • The patient has a known hypersensitivity to any portion of the device material or the individual components (see Device Description section in the IFU) such that the use of the WATCHMAN device is contraindicated.​
  • Any of the customary contraindications for other percutaneous catheterization procedures (e.g., patient size too small to accommodate TEE probe or required catheters) or conditions (e.g., active infection, bleeding disorder) are present.​
  • There are contraindications to the use of anticoagulation therapy, aspirin, or P2Y12 inhibitor. ​

WARNINGS

Implantation of the WATCHMAN Device should only be performed by interventional cardiologists and/or electrophysiologists who are trained in percutaneous and transseptal procedures and who have completed the WATCHMAN Physician Training program.​

  • This device has not been studied in pregnant or breastfeeding women. Careful consideration should be given to use of the Closure Device in pregnant and/or breastfeeding women due to the risk of significant exposure to x-rays and the use of anticoagulation medicine.​
  • Device selection should be based on accurate LAA measurements obtained using echocardiographic imaging guidance (TEE recommended in multiple angles [e.g., 0º, 45º, 90º, 135º]) to avoid improper Closure Device sizing.​
  • Do not release (i.e., unscrew) the WATCHMAN Device from the core wire unless all release criteria are satisfied to avoid suboptimal results.​
  • Potential for Closure Device embolization exists with cardioversion <30 days following Closure Device​ implantation; verify Closure Device position post-cardioversion during this period.​
  • Appropriate post-procedure drug therapy should be followed. See Post-Procedure Information section​ (in the IFU) for further detail. ​

PRECAUTIONS

  • The safety and effectiveness (and benefit-risk profile) of the WATCHMAN Device has not been established in patients for whom long-term anticoagulation is determined to be contraindicated.​
  • The LAA is a thin-walled structure. Use caution when accessing the LAA and deploying the Closure​ Device
  • Use caution when introducing a WATCHMAN Access System to prevent damage to cardiac structures.​
  • Use caution when introducing the Delivery System to prevent damage to cardiac structures.​
  • To prevent damage to the Delivery Catheter or Closure Device, do not allow the WATCHMAN Device to protrude beyond the distal tip of the Delivery Catheter when inserting the Delivery System into the Access Sheath.​
  • If using a power injector, the maximum pressure should not exceed 100 psi.​

PATIENT SELECTION FOR TREATMENT

In considering the use of the WATCHMAN FLX Device, the rationale for seeking an alternative to long-term anticoagulation therapy and the safety and effectiveness of the device compared to anticoagulation should be taken into account.​

  • The presence of indication(s) for long-term anticoagulation therapy, other than non-valvular atrial​ fibrillation (e.g. mechanical heart valve, hypercoagulable states, recurrent deep venous thrombosis).

Details regarding the indications, contraindications, warnings, and precautions for oral anticoagulants approved for patients with non-valvular atrial fibrillation are provided in their respective Instructions for Use. Of note:​

  • The safety and effectiveness (and benefit-risk profile) of the WATCHMAN FLX Device has not been established in patients for whom long-term anticoagulation is determined to be contraindicated.​
    Factors that need to be considered for the WATCHMAN FLX Device and implantation procedure include​ the following:​
    • Overall medical status, including conditions which might preclude the safety of a percutaneous, transcatheter procedure.​
    • Suitability for percutaneous, transseptal procedures, including considerations of:​
      • Cardiac anatomy relating to the LAA size and shape.​
      • Vascular access anatomy (e.g., femoral vein size, thrombus, or tortuosity).​
      • Ability of the patient to tolerate general or local anesthesia.​
      • Ability of the patient to undergo required imaging.​
    • Ability to comply with the recommended post-WATCHMAN FLX Device implant pharmacologic regimen (see Post-Procedure Information section in the eIFU) especially for patients at high risk for bleeding.​

ADVERSE EVENTS

Potential adverse events (in alphabetical order) which may be associated with the use of a left atrial appendage closure device or implantation procedure include but are not limited to:​
Air embolism, Airway trauma, Allergic reaction to contrast media, anesthetic, WATCHMAN Implant material, or medications, Altered mental status, Anemia requiring transfusion, Anesthesia risks, Angina, Anoxic encephalopathy, Arrhythmias, Atrial septal defect, Bruising, hematoma or seroma near the catheter insertion site, Cardiac perforation, Chest pain/discomfort, Confusion post procedure, Congestive heart failure, Contrast related nephropathy, Cranial bleed, Death, Decreased hemoglobin, Deep vein thrombosis, Device embolism, Device fracture, Device thrombosis, Edema, Embolism, Excessive bleeding, Fever, Fistula, Groin pain, Groin puncture bleed, Hematuria, Hemoptysis, Hypotension, Hypoxia, Improper wound healing, Inability to reposition, recapture, or retrieve the device, Infection/pneumonia, Interatrial septum thrombus, Intratracheal bleeding, Major bleeding requiring transfusion, Misplacement of the device/improper seal of the appendage/movement of device from appendage wall, Myocardial erosion, Nausea, Oral bleeding, Pericardial effusion/tamponade, Pleural effusion, Prolonged bleeding from a laceration, Pseudoaneurysm, Pulmonary edema, Renal failure, Respiratory insufficiency/failure, Stroke – Hemorrhagic, Stroke – Ischemic, Surgical removal of the device, TEE complications (e.g., throat pain, bleeding, esophageal trauma), Thrombocytopenia, Thrombosis, Transient ischemic attack (TIA), Valvular or vascular damage, Vasovagal reactions​

There may be other potential adverse events that are unforeseen at this time.​

92289690 D.4​